Droperidol, when used for sedation during ERCP, may prolong the QT interval

Gastrointestinal Endoscopy

Volumn 63, Issue 7, 2006, Pages 979-985

  Yimcharoen, Panot ^a   Fogel, Evan L ^a   Kovacs, Richard J ^a   Rosenfeld, Stephen H ^a   McHenry, Lee ^a   Watkins, James L ^a   Alazmi, Waleed M ^a   Sherman, Stuart ^a   Lehman, Glen A ^a  

^a Division of Toxicology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROPERIDOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; QT PROLONGATION; SEDATION;

ADJUVANTS, ANESTHESIA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CONSCIOUS SEDATION; DROPERIDOL; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33646924549     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2006.01.052     Document Type: Article

References (23)

1. Kao L.W., Kirk M.A., Evers S.J., et al. Droperidol, QT prolongation, and sudden death: what is the evidence?. Ann Emerg Med 41 (2003) 546-558
2. Anonymous. Droperidol. In: Kastrup E.K. (Ed). Drug facts and comparisons (2002), Facts and Comparisons, St. Louis, MO p. 994a-b
3. LoVecchio F., and Lewin N.A. Antipsychotics. In: Goldfrank L.R., Flomenbaum N.E., Lewin N.A., et al. (Eds). Goldfrank's toxicologic emergencies (2002), McGraw Hill, New York 875-885
4. Faigel D.O., Baron T.H., Goldstein J.L., et al. Guidelines for the use of deep sedation and anesthesia for GI endoscopy. Gastrointest Endosc 56 (2002) 613-617
5. Waring J.P., Baron T.H., Hirota W.K., et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 58 (2003) 317-322
6. Mullins M., Zwieten K.V., and Blunt J.R. Unexpected cardiovascular deaths are rare with therapeutic doses of droperidol. Am J Emerg Med 22 (2004) 27-28
7. MedWatch 2001 safety information summaries: Inapsine (droperidol). Available from: URL:http://www.fda.gov/medwatch/safety/2001/safety01.htm#inapsi.
8. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart 7 (1920) 353-370
9. Wooltorton E. Droperidol: cardiovascular toxicity and deaths. Can Med Assoc J 166 (2002) 932
10. Moss A.J. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 72 (1993) 23B-25B
11. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
12. Wilcox C.M., Forsmark C.E., and Cello J.P. Utility of droperidol for conscious sedation in gastrointestinal endoscopic procedures. Gastrointest Endosc 36 (1990) 112-115
13. Cohen J., Haber G.B., Dorai J.A., et al. A randomized double-blind study of the use of droperidol for conscious sedation during therapeutic endoscopy in difficult to sedate patients. Gastrointest Endosc 51 (2000) 546-551
14. Lischke V., Behne M., Doelken P., et al. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 79 (1994) 983-986
15. Guy J.M., Andre-Fouet X., Porte J., et al. Torsades de pointes and prolongation of the duration of QT interval after injection of droperidol. [in French]. Ann Cardiol Angeiol (Paris) 40 (1991) 541-545
16. Reilly J.G., Ayis S.A., Ferrier I.N., et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355 (2000) 1048-1052
17. Smith S.W., Martel M., Biros M., et al. QT lengthening after parenteral droperidol administration. Acad Emerg Med 9 (2002) 374-375
18. Faber T.S., Zehender M., and Just H. Drug-induced torsade de pointes. Incidence, management, and prevention. Drug Saf 11 (1994) 463-476
19. Adamantidis M.M., Kerram P., and Dupuis B.A. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 8 (1994) 391-407
20. Bursill J.A., Wyse K.R., and Campbell T.J. Quinidine but not disopyramide prolongs cardiac Purkinje fiber action potentials after a pause. J Cardiovasc Pharmacol 23 (1994) 833-837
21. Zehender M., Hohnlofer S., and Just H. QT interval prolongating drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drugs Ther 5 (1991) 515-530
22. Drug-induced ventricular tachycardia associated with prolongation of the QT interval is a well-recognized form of drug toxicity termed Torsades de Pointes (TdP). Available from: URL:http://www.torsades.org.
23. Braunwald E. Specific arrhythmias: diagnosis and treatment. Heart disease: a textbook of cardiovascular medicine. 6th ed. (2001), WB Saunders, Philadelphia 803-863